Teva Recalls Metoclopramide Tablets Nationwide Due to Foreign Contamination

Teva Pharmaceuticals USA, Inc has voluntarily initiated a nationwide recall of Metoclopramide Tablets, USP 10 mg, packaged in 100-count bottles (NDC 0093-2203-01). The recall affects lot number 5420094, which carries an expiration date of September 30, 2027. Manufactured in Croatia by Pliva Hrvatska d.o.o. and distributed by Teva from its headquarters in Parsippany, New Jersey, the tablets were found to be contaminated by the presence of foreign tablets or capsules—a serious manufacturing deviation that could pose risks to patient safety if the wrong medication is consumed.

The US Food and Drug Administration (FDA) classified the recall as Class II, indicating that the use of the product may cause temporary or medically reversible adverse health consequences, but the probability of serious harm is remote. The recall, initiated on May 23, 2025, is still ongoing and was communicated to consignees via letter. A total of 36 612 cartons are affected, and while no public press release has been issued to date, the agency’s Enforcement Report reflects the ongoing nature of the investigation under Event ID 96919.

Metoclopramide is commonly prescribed for short-term treatment of gastroesophageal reflux disease (GERD) in patients who do not respond to conventional therapy. It is also used to relieve symptoms of slow stomach emptying (gastroparesis) in patients with diabetes. Pharmacists are advised to closely examine their inventory for the affected lot number and follow Teva’s instructions for return or disposal to prevent potential dispensing errors.